Company / Free Cash Flow
BridgeBio Pharma, Inc. Free Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$447.0M
FY2025
5-year range
-$521.7M / -$256.2M
FY2021-FY2025
Trend
+14.3%
vs FY2024
Sector context
#184 of 194
Health Care
What the data says
Among 194 Health Care companies, BridgeBio Pharma, Inc. is in the bottom 5% for free cash flow. Free Cash Flow returned to growth in FY2025 after 3 years of decline, reaching -$447M.
Based on SEC 10-K filings.
-$447M in FY2025.
Improved from -$511M to -$447M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 194This company -$447.0M Sector average $470.8M
▼
-194.9% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 14.3% year-over-year.
- Ranks #184 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2017.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$447.0M | +14.3% |
| FY2024 | -$521.7M | -2.0% |
| FY2023 | -$511.2M | -20.5% |
| FY2022 | -$424.3M | -65.6% |
| FY2021 | -$256.2M | +37.1% |
| FY2020 | -$407.2M | -58.9% |
| FY2019 | -$256.2M | -84.6% |
| FY2018 | -$138.8M | -239.0% |
| FY2017 | -$41.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026